At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed NSCLC
- ✓Locally advanced stage IIIA or IIIB disease that is unresectable
- ✓No stage IV disease
- ✓Requires radiotherapy
- ✕No prior systemic chemotherapy for NSCLC
- ✕No prior radiotherapy to the chest
- ✕No peripheral neuropathy ≥grade 2
- ✕No uncontrolled infection
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Study of PS-341 in Combination With Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non-small Cell Lung Cancer (NSCLC)
In Brief
A Phase 2 clinical trial evaluating 3-dimensional conformal radiation therapy, bortezomib, and 2 other interventions for Recurrent Non-small Cell Lung Cancer and 2 related conditions. Completed, enrolled 52 participants across 143 sites.
Detailed Summary
This phase I/II trial (phase I closed to accrual as of 09/29/2009) is studying the side effects and best dose of bortezomib, paclitaxel, and carboplatin when given with radiation therapy and to see how well they work in treating patients with stage IIIA or stage IIIB non-small cell lung cancer that cannot be removed by surgery. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Bortezomib may increase the effectiveness of paclitaxel and carboplatin by making tumor cells more sensitive to the drugs. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving bortezomib, paclitaxel, and carboplatin together with radiation therapy may kill more tumor cells.
Study Details
Timeline
Interventions
Given IV
Given IV
Given IV